top of page

Clinical Pipeline


Q Therapeutics has a deep pipeline, with significant market potential backed by a strong intellectual property position.

Q Therapeutics is actively preparing for first-in-human clinical trials in transverse myelitis and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) as an orphan drug. Trial start-up is expected in 2019.

Orphan drug designation has significant regulatory, financial and competitive advantages, including:


  • High rates of regulatory approval

  • Shorter development timelines including FDA Fast Track designation, and

  • Market exclusivity. 

Existing safety and manufacturing data may also support Investigational New Drug (IND) filings for spinal cord injury and multiple sclerosis and , providing significant cost and time savings for each additional indication.

bottom of page